1MK Stock Chart & Stats
€0.06
>-€0.01(-5.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-5.00%)
Day’s Range― - ―
52-Week Range€0.05 - €0.21
Previous CloseN/A
Volume0.00
Average Volume (3M)4.78K
Market Cap
€18.94M
Enterprise Value€39.82M
Total Cash (Recent Filing)€2.35M
Total Debt (Recent Filing)€11.83M
Price to Earnings (P/E)1.5
Beta0.43
Next Earnings
Apr 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding195,260,220
10 Day Avg. Volume0
30 Day Avg. Volume4,776
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.65
Price to Sales (P/S)1.55
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€7.75M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue rebound shows that demand for Cellvizio can recover meaningfully after a weak period. If commercial adoption and procedure activity continue improving, higher scale could support better operating leverage and strengthen the platform’s market position over the next several quarters.
Strong Gross MarginA consistently high gross margin indicates that Cellvizio and related consumables retain substantial value relative to direct costs. This provides an attractive foundation for future profitability if revenue expands and fixed operating expenses become better absorbed across the installed technology base.
Debt ReductionThe substantial reduction in total debt is a meaningful balance-sheet improvement and may lower financing pressure compared with the prior year. Deleveraging can preserve more future cash for commercial investment and reduce the burden of refinancing, even though overall financial flexibility remains constrained.
Bears Say
Deep Operating LossesThe deeply negative operating margin shows that the core business is not yet covering its operating cost base, despite the revenue rebound and strong gross margin. Without sustained cost improvement or much greater scale, ongoing losses could continue consuming resources and delay a durable path to profitability.
Persistent Cash BurnNegative operating and free cash flow indicate that reported business activity is still not funding ongoing operations. Continued cash burn may require external funding or balance-sheet actions, limiting financial resilience and potentially restricting investment in sales, clinical evidence, and product expansion.
Negative Shareholders’ EquityPersistent negative equity reflects accumulated deficits and leaves the company with limited balance-sheet flexibility. This weak capital position heightens solvency and refinancing risk, while also making it harder to absorb further operating losses or finance growth without additional capital support.
MAUNA KEA TECHNOLOGIES News
1MK FAQ
What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?
MAUNA KEA TECHNOLOGIES lowest stock price was €0.05 and its highest was €0.21 in the past 12 months.
What is MAUNA KEA TECHNOLOGIES’s market cap?
MAUNA KEA TECHNOLOGIES’s market cap is €18.94M.
When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?
MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Apr 22, 2027 which is in 172 days.
How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?
MAUNA KEA TECHNOLOGIES released its earnings results on Oct 08, 2026. The company reported -€0.026 earnings per share for the quarter.
Is MAUNA KEA TECHNOLOGIES overvalued?
According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued.
Does MAUNA KEA TECHNOLOGIES pay dividends?
MAUNA KEA TECHNOLOGIES does not currently pay dividends.
What is MAUNA KEA TECHNOLOGIES’s EPS estimate?
MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAUNA KEA TECHNOLOGIES have?
MAUNA KEA TECHNOLOGIES has 195,260,220 shares outstanding.
What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?
MAUNA KEA TECHNOLOGIES reported an EPS of -€0.026 in its last earnings report. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?
Currently, no hedge funds are holding shares in DE:1MK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MAUNA KEA TECHNOLOGIES
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.